Undecimal Bio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Undecimal Bio - overview
Established
2026
Location
Tel Aviv, -, Israel
Primary Industry
Biotechnology
About
Based in Israel, Undecimal Bio, operates as a provider of RNA delivery technology for therapeutic development. Based in Tel Aviv, Israel and founded in 2026, Undecimal Bio provides RNA delivery technology for therapeutic development. In October 2026, Undecimal Bio raised USD 18 mn in Seed funding by 4BIO Capital Partners, Entree Capital, Harel Finance Alternative, IQ Capital, Kerna Ventures, Saras Capital, and Verve Ventures. The funding will be used to advance its delivery molecule and therapeutic siRNA platform, continue testing in primary human cells, and expand its UK team.
Undecimal Bio specializes in AI-driven delivery systems for small interfering RNA (siRNA) therapeutics, utilizing combinatorial chemistry and transformer-based AI capabilities. Their offerings focus on targeting specific tissues, particularly in the kidney and vascular system, where traditional delivery methods are inadequate. The company systematically evaluates numerous delivery candidates to identify molecules that facilitate effective intracellular delivery, addressing unmet medical needs in treating renovascular diseases. Their primary customers include pharmaceutical companies and investors interested in RNA medicine.
Undecimal Bio operates on a revenue model that incorporates partnerships and collaborations with pharmaceutical companies. These partnerships may involve revenue-sharing agreements for co-development and commercialization of siRNA delivery products, often structured as contractual partnerships with upfront fees and milestone payments. The company’s revenue dynamics are influenced by its commitment to developing effective delivery mechanisms for siRNA-based therapies, establishing a pipeline approach to product development. The company plans to advance its delivery molecule and therapeutic siRNA platform, continue testing in primary human cells, and expand its UK team.
Current Investors
IQ Capital, Entree Capital, Harel Finance Alternative, 4BIO Capital Partners, Verve Ventures, Saras Capital, Kerna Ventures
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.undecimalbio.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Undecimal Bio - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Seed | Completed | Undecimal Bio | - |
Displaying 1 - 1 of 1

Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.